Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis

Bicistronic-CD19/22 CAR-T therapy has induced sustained remission in pediatric patients with refractory LN. Although the treatment triggered severe complications-HLH/TMA. These complications were manageable with aggressive supportive therapy, underscoring the importance of meticulous patient screening before CAR-T administration. This therapy offers a promising treatment strategy for refractory LN.